According to a recent LinkedIn post from Isomorphic Labs, Chief Research Officer Sarah Skerratt is scheduled to participate in the Revolution 2026 event in Washington, D.C. The post indicates she will join a panel of industry figures to discuss current applications of artificial intelligence in drug discovery, future opportunities, and the ethical responsibilities around AI-enabled innovation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also highlights the company’s internal drug design engine, IsoDDE, which is described as enabling exploration of novel areas of chemistry and biology and accelerating the progression from early research toward potential new medicines. For investors, this emphasis on AI-driven discovery and external thought-leadership visibility may suggest continued investment in proprietary platforms and a strategic push to position Isomorphic Labs within the competitive landscape of AI-enabled pharmaceutical R&D.